REMARKS

Claims in Groups I through IV are all drawn to oligonucleotides designed to enrich for lysine in a reserve protein from maize (Group I, claims 1-3, 23, 42-50, 52-55, 57-64, 69-75, 77-82), non-maize cereal plants (Group II, claims 1-3, 23, 42-50, 56, 58-59, 61, 63, 69-72, 76, 77-78, 80-81), leguminous or cruciferous plants (Group III, claims 1-3, 23, 42-49, 51, 56, 58-59, 61, 63, 69-72, 76, 77-78, 80-81), and non-cereal, non leguminous, non cruciferous plants (Group IV, claims 1-3, 23, 42-49, 56, 58-59, 61, 63, 69-72, 76, 77-78, 80-81). Each group also concerns host cells and plants from the same species transformed with the recombinant nucleotide.

In the Office Action, Examiner asserts that a gamma-zein protein is to be considered as the sole reserve protein in Group I, yet mentions only "a reserve protein" for Groups II-IV of the invention. We point out that the elected claims cover oligonucleotides designed to enrich for lysine in any reserve protein from maize (i.e., not only gamma-zein proteins), as well as to maize host cells and maize plants transformed with these sequences.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully sugmitted

Date:

Kristina Bioker-Brady, Ph.D., P.C

Reg/No. 39.10

Clark & Elbing LLP 101 Federal Street

Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045